Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 21,700 shares, an increase of 149.4% from the March 31st total of 8,700 shares. Based on an average daily trading volume, of 17,100 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.7% of the company’s stock are sold short.
Addex Therapeutics Stock Up 4.5 %
Shares of Addex Therapeutics stock opened at $16.10 on Friday. The firm has a market cap of $17.07 million, a P/E ratio of -0.84 and a beta of 1.66. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90. The business has a 50-day moving average price of $14.55 and a 200 day moving average price of $9.72.
Institutional Trading of Addex Therapeutics
An institutional investor recently raised its position in Addex Therapeutics stock. Armistice Capital LLC boosted its position in Addex Therapeutics Ltd (NASDAQ:ADXN – Free Report) by 103.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 537,000 shares of the company’s stock after buying an additional 273,000 shares during the quarter. Armistice Capital LLC owned approximately 65.33% of Addex Therapeutics worth $206,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.14% of the company’s stock.
Addex Therapeutics Company Profile
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.
Recommended Stories
- Five stocks we like better than Addex Therapeutics
- How to Invest in Insurance Companies: A Guide
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Tickers Leading a Meme Stock Revival
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Investing in the High PE Growth Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
